Delving into the Latest Updates on Shanghai Shiling Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Endocrinology and Metabolic Disease

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

MAO-B(Monoamine oxidase B)	1

第一部分：PK/PD探索研究 1)评价甲磺酸雷沙吉兰透皮贴剂给药一周（4天/贴+3天/贴）的安全性。 2)评价甲磺酸雷沙吉兰透皮贴剂给药一周（4天/贴+3天/贴）的药代动力学和药效动力学特征。 3)比较甲磺酸雷沙吉兰透皮贴剂与甲磺酸雷沙吉兰片的药代动力学和药效动力学特征。 4)评价甲磺酸雷沙吉兰透皮贴剂给药后的黏附性、刺激性和致敏性。第二部分：多次给药生物利用度研究 1)比较甲磺酸雷沙吉兰透皮贴剂与甲磺酸雷沙吉兰片在健康人体内连续给药的相对生物利用度。 2)比较甲磺酸雷沙吉兰透皮贴剂与甲磺酸雷沙吉兰片多次给药的药效动力学特征。 3)评价甲磺酸雷沙吉兰透皮贴剂和甲磺酸雷沙吉兰片多次给药的安全性。 4)评价甲磺酸雷沙吉兰透皮贴剂多次给药的黏附性、刺激性和致敏性。第三部分：不同部位生物利用度研究 1)比较甲磺酸雷沙吉兰透皮贴剂不同部位给药的生物利用度。 2)评价甲磺酸雷沙吉兰透皮贴剂的安全性、黏附性、刺激性和致敏性。

[Translation]

Part I: PK/PD Exploratory Study 1) Evaluate the safety of rasagiline mesylate transdermal patch for one week (4 days/patch + 3 days/patch). 2) Evaluate the pharmacokinetic and pharmacodynamic characteristics of rasagiline mesylate transdermal patch for one week (4 days/patch + 3 days/patch). 3) Compare the pharmacokinetic and pharmacodynamic characteristics of rasagiline mesylate transdermal patch and rasagiline mesylate tablets. 4) Evaluate the adhesion, irritation and sensitization of rasagiline mesylate transdermal patch after administration. Part II: Multiple-dose bioavailability study 1) Compare the relative bioavailability of rasagiline mesylate transdermal patch and rasagiline mesylate tablets after continuous administration in healthy humans. 2) Compare the pharmacodynamic characteristics of rasagiline mesylate transdermal patch and rasagiline mesylate tablets after multiple administration. 3) Evaluate the safety of multiple administration of rasagiline mesylate transdermal patch and rasagiline mesylate tablets. 4) Evaluate the adhesion, irritation and sensitization of multiple administration of rasagiline mesylate transdermal patch. Part III: Bioavailability study at different sites 1) Compare the bioavailability of rasagiline mesylate transdermal patch at different sites. 2) Evaluate the safety, adhesion, irritation and sensitization of rasagiline mesylate transdermal patch.

Start Date-

Sponsor / Collaborator

Shanghai Shiling Pharmaceutical Co., Ltd.

[+1]

100 Clinical Results associated with Shanghai Shiling Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai Shiling Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Shanghai Shiling Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Shiling Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1

1

Login to view more data